Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 389.62M shares rose 76.9% year over year, ahead of the +52.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 15.4% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +76.9% holds above the trailing-twelve-month pace of +52.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
389.62M+15.4% QoQ
Last fiscal yearDec 2025
280.19M+38.9% YoY
LTMMar 2026
322.14M+52.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.9%——
1 year+38.9%——
3-year CAGR+22.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
280.19M USD
Year-over-year change
+38.9%
4-year CAGR
+18.0%

Weighted Avg Shares vs competitors

How SGMO compares with its peers on the latest reported figures

  • SGMO's LTM Mar 2026 weighted avg shares of 322.14M shares is the highest of the 11 companies compared; the peer median is 89.31M shares.
  • Its year-over-year change of +52.9% is the 4th highest of 11, against a peer median of +24.8%.
  • Over three fiscal years its annual growth of +22.0% compares with a peer median of +13.4%.
SGMO Competitors Peer median
Weighted Avg Shares for SGMO and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M +0.4%+1.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
Peer median (excluding SGMO) 89.31M+24.8%+13.4%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.